Hyperuricemia and oxidative stress participate in the pathophysiology of hypertension and its complications. Xanthine dehydrogenase (XDH) produces urate and, in its oxidase isoform, reactive oxygen species.
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Associations of Hypertension and Its Complications with Variations in the Xanthine Dehydrogenase Gene
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Here we have studied whether or not the genetic variations in XDH could be implicated in hypertension and 
Introduction
Hypertension is one of the most common and important risk factors for stroke, coronary heart diseases (CHD), and chronic kidney disease (CKD). The major contribution to the etiology of this disorder is proposed to come from the combined effects of genes that modify the response of blood pressure to environmental stresses, including diet and environmental susceptibility genes (1) . This multifactoral trait increases the affected individuals' risks of stroke, CHD, and CKD, and is one of the leading causes of morbidity and mortality in adults (2) . The population-wide application of preventative measures and analyses of candidate genes to predict modifiable risks, in addition to developing new treatments for hypertension and its complications, are thus very worthwhile (3, 4) .
Xanthine oxidoreductase (XOR), best known as the ratelimiting enzyme of the purine degradation pathway, converts hypoxanthine to xanthine and xanthine to uric acid (UA) via its two interconvertible isoforms, xanthine dehydrogenase (XDH) and xanthine oxidase (XO); in its oxidase isoform, XOR produces reactive oxygen species (ROS) (5) . Hyperuricemia is commonly seen in hypertensive patients (6) . Several large epidemiologic studies have identified an association between increased serum UA levels and cardiovascular risk in the general population (7) (8) (9) (10) , among patients with hypertension (11, 12) , between increased serum UA levels and renal failure in the general population (13, 14) , and among patients with hypertension (15) . ROS plays critical roles in the pathogenesis of a number of cardiovascular diseases, including atherosclerosis, hypertension, diabetes mellitus, and heart failure (16). They have also been implicated as important mediators of the progression of renal injury in different animal models of hypertension (17) (18) (19) (20) . The conversion of XDH to XO and increased XO activity have been reported in some pathological conditions, including hypertension (21-23) and atherosclerosis (24) . Importantly, treatments with XO inhibitors were recently reported to normalize ROS levels in microvessels from rats fed a high-salt diet (25) and to promote endothelial-dependent relaxation in arteries from SHR (26) . These findings suggest that XO is an important source of ROS in patients with hypertension. Therefore, the XDH gene is suspected to be associated with constitutional susceptibility to hypertension and its complications.
So far, there are no reports about the relation between variations in human XDH gene (XDH) and hypertension and its complications. Human XDH, located on chromosome 2 at p23.1 (27) , consists of 36 exons that encode a 1,333-amino acid protein. The aim of the present study was to screen for possible genetic variations in the promoter and all exon regions of XDH in 48 patients with hypertension. By genotyping the missense mutations and common single nucleotide polymorphisms (SNPs) in a large hypertensive population and the general population, we further assessed the role of these genetic variations in hypertension and clarified the contributions of common SNPs to hypertension and its complications, including atherosclerosis and CKD.
Methods

Hypertensive Population
The characteristics of the hypertensive population analyzed in the present study are summarized in Table 1 . A total of 953 hypertensive subjects (522 men and 431 woman, average age: 65.1±10.5 years old) were recruited from the Division of Hypertension and Nephrology at the National Cardiovascular Center, as reported previously (28, 29) . Briefly, 92% of study subjects (880 subjects) were diagnosed with essential hypertension, and the rest had secondary hypertension. The hypertension criteria were a systolic blood pressure (SBP) above 140 mmHg and/or a diastolic blood pressure (DBP) above 90 mmHg, or the use of antihypertensive agents. Hyperlipidemia was defined by a total cholesterol level ≥ 220 mg/dL or the taking of antihyperlipidemia medication. Diabetes mellitus was defined by a fasting plasma glucose level ≥ 126 mg/dL, nonfasting plasma glucose ≥ 200 mg/dL, HbA1c ≥ 6.5%, or the taking of antidiabetic medication. Smoking was defined as current smoking. Total cholesterol, high-density lipoprotein (HDL) cholesterol, triglyceride, and low-density lipoprotein (LDL) cholesterol levels were measured as previously described (30) . Study subjects underwent routine laboratory tests, including examinations of electrolytes, renal function, blood glucose, HbA1c, plasma renin activity (PRA), and plasma aldosterone concentration (PAC) by radioimmunoassay.
Evaluation of Atherosclerosis and CKD in the Hypertensive Population
Carotid ultrasonography was used to measure mean intimamedial thickness (IMT) using ultrasonography (SSA-390A; Toshiba, Tokyo, Japan) as previously described (31) . IMT above 1.0 mm in either the left or right common carotid artery defined with the presence of an atherosclerotic lesion. We also assessed arterial stiffness using brachial-ankle-pulse wave velocity (ba-PWV) measured by form ABI (Omron Health Care, Kyoto, Japan) as described in a previous report (32) . Estimated creatinine clearance (Ccr) determined with the Cockcroft-Gault formula (33) was used for the evaluation of CKD. We defined CKD as Ccr < 60 mL/min according to Values are expressed as mean±SD.
the guidelines of the National Kidney Foundation (34).
Screening of Genetic Variations in XDH
We sequenced the promoter region and all exons of XDH in 48 randomly chosen patients with hypertension. Blood samples were obtained from all hypertensive patients, and genomic DNA was isolated from peripheral blood leukocytes using an NA-3000 nucleic acid isolation system (Kurabo, Osaka, Japan) (35) . All exons with their flanking sequences and 1 kb of the promoter region were directly sequenced with an ABI PRISM 3700 DNA analyzer (Applied Biosystems, Foster City, USA) as described previously (36) using 38 sets of primers. Information on the primers and PCR conditions is available on request. The sequences obtained were examined for the presence of variations using Sequencher software (Gene Codes, Ann Arbor, USA), followed by visual inspection.
Genotyping of Missense Mutations and Common SNPs in Hypertensive Subjects and the General Population
Three missense mutations and eight common SNPs with a minor allelic frequency of greater than 10% were genotyped in 953 hypertensive patients and in 1,818 subjects (835 men and 983 women) participating in the Suita Study. We chose just one common SNP for genotyping among SNPs that show strong linkage disequilibrium (LD) with an r 2 above 0.5. The sample selection and study design of the Suita Study were described previously (37) . Briefly, the subjects visited the National Cardiovascular Center every 2 years for general health checkups. In addition to a routine blood examination that included lipid profiles, glucose levels, blood pressure, and anthropometric measurements, a physician or nurse administered questionnaires covering the subject's personal history of cardiovascular diseases, including angina pectoris, myocardial infarction, and/or stroke. Nondrinkers were those who had had no drink in the past month. Current drinkers were those who were drinking at least 30 mL of ethanol per day, and past drinkers were those who used to drink that much in the past but not in the present. Subjects were regarded as having a disease if they were currently taking antihypertensive, antihyperlipidemic, or antidiabetic medication. Sevenhundred and ninety-five subjects were diagnosed as having hypertension. All of the participants were Japanese. The characteristics of the subjects in the Suita Study are summarized in Table 2 .
The TaqMan-PCR (Roche Molecular Systems, Pleasanton, USA) method was used for genotyping (35) . The sequences of PCR primers and probes for the TaqMan-PCR method are available on request. All of the participants in the genetic analysis in the present study gave their written informed consent. All clinical data, as well as the results of sequencing and genotyping, were anonymous. The study protocol was approved by the Ethics Review Committee of the National Cardiovascular Center, Japan.
Statistical Analysis
Values are expressed as means±SD. The distribution of patient characteristics between men and women in the general population and in the hypertensive population was analyzed with Student's t-test or χ 2 analysis. The associations of genetic models with blood pressures were tested with a logistic regression analysis considering potential confounding risk variables, including age, body mass index (BMI), present illness (hyperlipidemia and diabetes mellitus), lifestyle (current smoking and drinking), and antihypertensive medication by sex. For multivariate risk predictors, the adjusted odds ratios (ORs) were given with 95% confidence intervals. The relationship between genotype and risk of hypertension was expressed in terms of ORs adjusted for possible confounding factors, including age, BMI, present illness (hyperlipidemia and diabetes mellitus), and lifestyle (current smoking and drinking) by sex. The relationship between genotype and risk of atherosclerosis or CKD in hypertensive patients was expressed in terms of ORs adjusted for possible confounding factors, including age, sex, BMI, LDL cholesterol, HbA1c, SBP, and DBP for atherosclerosis; and age, BMI, SBP, DBP, and diabetes mellitus for CKD. For each pair of SNPs, the pairwise LD parameters, D′ and r 2 , were calculated on the basis of the genotyping data using SNPAlyze version 3.1 Pro (Dynacom, Mobara, Japan). All analyses were performed with SAS statistical software release 8.2 (SAS Institute, Cary, USA) or JMP statistical software version 4.0 (SAS Institute). Statistical significance was established at p< 0.05. 
Results
Identification of Genetic Variations in XDH
As shown in Table 3 , we identified 3 missense mutations in XDH. Nine of the 48 individuals had a G-to-A substitution at nucleotide 26390 in exon 7, leading to an amino acid substitution from Gly to Arg at position 172 (G172R). One individual had a G-to-A substitution at nucleotide 64606 in exon 26, leading to a change from Ala to Thr at position 932 (A932T). Three of the 48 individuals had an A-to-C substitution at nucleotide 67873 in exon 31, leading to the substitution of Asn with Thr at position 1109 (N1109T). These missense The A of the ATG of the initiator Met codon is denoted nucleotide +1, as recommended by the Nomenclature Working Group (Hum Mut 1998; 11: 1-3). The nucleotide sequence (GenBank Accession ID: NT_022184.14) was used as a reference sequence. The apparent linkage disequilibrium (LD), defined by r 2 more than 0.5, was indicated by a in the LD column. XDH, xanthine dehydrogenase gene; SNP, single nucleotide polymorphism; UTR, untranslated region. mutations were all found in heterozygous form. In addition, we identified five synonymous variations (26382G>A in exon 8, 80868C>T in exon 10, 47686C>T in exon 22, 65747T>C in exon 28, and 75121G>A in exon 35) encoded for E209 (minor allelic frequency, 0.085), for V279 (0.064), for I787 (0.33), for F1010 (0.135), and for E1239 (0.011), respectively. Twenty-nine additional variations in the introns and a 3′-untranslated region were also detected. Among all the variations, there were 15 common polymorphisms with a minor allelic frequency of over 0.1 (11488C>G, 26504C>T,  37387A>G,  39048A>G,  44408A>G,  46748G>C,  46774G>A,  47879A>G,  49096G>A, 49245A>T, 50298C>T, 65050-65051 ins C, 66292C>G, 67157A>G, and 69901A>C).
Characteristics of Hypertensive Subjects with Missense Mutations in Homozygous Form
After genotyping the three missense mutations in 953 patients with hypertension, including secondary hypertension, we found one subject with G172R and three with N1109T in homozygous form. The characteristics of these four patients with rare missense mutations in the homozygous form are shown in Table 4 . All four had resistant hypertension despite antihypertensive drug therapy. One of the patients with N1109T (patient 2) had hyperuricemia and was taking allopurinol. The patient with G172R (patient 1) and the two others with N1109T (patients 2 and 4) had hyperlipidemia. Patients 1 and 4 had low PRA levels (0.1 and 0.4 ng/mL/h, respectively) and high average IMT values (1.0 mm for both). Patient 1 had low Ccr (50.8 mL/min) and overt proteinurea. Three of the four patients had high ba-PWV values: no data , 99 to 109 mEq/L; creatinine, 0.6 to 1.1 mg/dL; Ccr, <60 mL/min; UA, 3.6-7.0 mg/ dL; PRA, 0.2 to 2.7 ng/mL/h; PAC, 2 to 13 ng/dL; FBS, <126 mg/dL; HbA1c, <6.5%; ba-PWV, <1,400 cm/s; average IMT, <1.0 mm. on ba-PWV were available for patient 2.
Associations of 11 Variations with Hypertension in the General Population
Three missense mutations (G172R, A932T, and N1109T) and eight common SNPs (11488C>G, 37387A>G, 44408A>G, 46774G>A, 47686C>T, 49245A>T, 66292C>G, and 69901A>C) were used for the association studies in the casecontrol setting for men and woman separately. Adjusted for age, BMI, present illness (hyperlipidemia and diabetes mellitus), and lifestyle (smoking and drinking), a logistic regression analysis of the case-control study showed that three of the eight SNPs were significantly associated with hypertension in men: TT vs. CC +CT for 47686C>T (exon 22, OR: 1.52, p= 0.045) and CC vs. AC +AA for 69901A>C (intron 31, OR: 3.14, p= 0.039) in the recessive model, and AC+CC vs. AA for 67873A>C (N1109T) (exon 31, OR: 1.84, p= 0.018) in the dominant model (Table 5) .
SBP was 2.44 mmHg higher in women with the AC+CC genotype of the positively associated SNP 69901A>C in XDH than in women with the AA genotype (p= 0.037). Although there was no significant difference in SBP or DBP between the AC +CC and AA genotypes of 69901A>C in men, DBP was 4.18 mmHg higher in men with the CC genotype of 69901A>C than in men with the AA+AC genotype (p= 0.088). DBP was 2.75 mmHg higher in men with the AC +CC genotype of the positively associated SNP 67873A>C than in men with the AA genotype (p= 0.021) ( Table 6) .
Regarding the three missense mutations, there were 6 subjects with a homozygote allele in XDH G172R and 5 subjects with one in N1109T, but no subjects with one in A932T. The subjects with a homozygote allele in G172 and N1109T did not have any specific clinical characteristics (data not shown).
Association of 11 Variations with Carotid Atherosclerosis in Hypertensive Subjects
Three missense mutations (G172R, A932T, and N1109T) and eight common SNPs (11488C>G, 37387A>G, 44408A>G, 46774G>A, 47686C>T, 49245A>T, 66292C>G, and 69901A>C) were tested for associations with carotid atherosclerosis in patients with essential hypertension. After the full adjustment for all confounding factors (age, BMI, SBP, DBP, current smoking status, alcohol consumption, and presence of diabetes mellitus and dyslipidemia), only one polymorphism (69901A>C) was found to be independently associated with carotid atherosclerosis in the dominant model (χ 2 = 4.82, p= 0.028). Other factors-age (χ 2 = 67.70, p< 0.001), SBP (χ 2 = 15.11, p< 0.001), and DBP (χ 2 = 4.28, p= 0.039)-were related to carotid atherosclerosis. We compared IMT and ba-PWV values among the alleles in XDH 69901A>C. There were no significant differences between alleles in either IMT or ba-PWV. However, ba-PWV values tended to differ significantly (AA: 1,794, AC: 1,825, CC: 2,024 cm/s, p= 0.075) in XDH 69901A>C. These findings may indicate that hypertensive patients with the CC of XDH 69901A>C are more susceptible to atherosclerosis than those with the A allele.
Associations of 11 Variations with Chronic Kidney Disease in Hypertensive Subjects
We divided the essential hypertensive patients into two groups using a cutoff estimate of Ccr 60 mL/min. The CKD group (Ccr < 60 mL/min) showed significantly higher age (p< 0.001), lower BMI (p< 0.001), and lower DBP (p< 0.001) than the non-CKD group. As shown in Table 7 , after adjustment for age, BMI, SBP, DBP, and the number of patients that suffer from diabetes mellitus, logistic regression analysis showed that one SNP (66292C>G) of the 11 variations was strongly associated with chronic kidney disease in the recessive model in men (OR= 2.36, p= 0.0006). This significant association was still positive after a Bonferroni correction (p= 0.0006 < 0.05/11). However, there was no significant difference in Ccr value between GG and CC+CG in XDH 66292C>G in male hypertensive patients (GG: 84.73±39.14 vs. CC +CG: 80.32±73.26 mL/min, p= 0.384).
Discussion
The present study is the first to examine the relationships between genetic variations in XDH and hypertension or its complications in human. After the screening for possible genetic variations in the promoter and all exon regions of XDH in 48 patients with hypertension, 11 variations, including 3 missense mutations and 8 common SNPs, were genotyped and used to assess the roles of these genetic changes in hypertension in a large population of hypertensive subjects and in a general population. The 4 hypertensive patients with a rare missense mutation (G172R or N1109T) in homozygous form had hypertension. More importantly, 67873A>C (N1109T) also showed a positive association with hypertension in men in a multivariable logistic analysis. In addition, DBP was 2.75 mmHg higher in men with the AC+CC genotype of 67873A>C than in men with the AA genotype (p= 0.021). This indicates that 67873A>C may be a functional risk factor for hypertension in males. Another two SNPs, 47686C>T in the exon region and 69901A>C in the intron region, were also found to be significantly related to hypertension in men. Furthermore, SBP was 2.44 mmHg higher in women with the AC+CC genotype of 69901A>C than those with the AA genotype (p= 0.037). Since a significant association was obtained in the multivariable analysis with adjustment for confounding risk factors, including age, BMI, present illness (hyperlipidemia and diabetes mellitus), and lifestyle (current smoking and drinking) by sex, these three SNPs appear to be independent risk factors for hypertension. The C allele of 69901A>C was associated with greater susceptibility in male subjects. In females, there was a significant association between 69901A>C and blood pressure. Although there was no significant difference in SBP or DBP between the AC+CC and AA genotypes of 69901A>C in men, DBP was 4.18 mmHg higher in men with the CC genotype of 69901A>C than in men with the AA+AC genotype (p= 0.088). Taking these findings together, we speculate that, among males, those with 67873A>C (N1109T) were most susceptible to hypertension. This is also the first report to show a positive relationship between SNPs of XDH and CKD in hypertensive patients. It is well reported that age, sex, blood pressure, BMI, and diabetes mellitus are all factors in renal dysfunction (38) (39) (40) (41) . Our results also showed that age, DBP, and BMI differed significantly between hypertensive patients with Ccr < 60 mL/min and those with Ccr ≥ 60 mL/min. But no significant difference in SBP or the number of diabetes mellitus patients was found with or without CKD in these hypertensive subjects. After adjustment for age, sex, BMI, SBP, DBP, and the number of patients having diabetes mellitus, the logistic regression analysis showed that only one SNP (66292C>G) was strongly associated with CKD in hypertensive patients. This indicates that 66292C>G may be an independent risk factor for CKD in hypertensive patients.
SNP 69901A>C was found to be significantly associated with carotid atherosclerosis in hypertensive patients in our study. Although we did not find a significant difference between genotypes in any of the various atherosclerotic variables, hypertensive patients with the A allele of 69901A>C tend to be more susceptible to atherosclerosis than those with the C allele.
How the SNPs of XDH influence the pathogenesis of hypertension and its complications, including atherosclerosis and CKD, remains unclear. Among the four SNPs that showed a positive association with hypertension or with atherosclerosis and CKD in hypertensive patients, 67873A>C and 47686C>T are in exon regions, and 69901A>C and 66292C>G are in intron regions. 67873A>C causes a missense mutation in exon 31, leading to an amino acid substitution from Asn to Thr at position 1109. But 47686C>T does not result in a change in amino acids. In addition, the three missense mutations, 26390G>A (G172R), 64606G>A (A932T), and 67873A>C (N1109T), occurred in highly conserved residues among different species, all resulting in a hydrophilic amino acid substitution, which may influence reactive centers of enzymes. The XDH protein consists of three functional subunit domains, each of which binds a different cofactor, from amino acids 1 to 165 for binding 2Fe2S2, from 226 to 531 for binding flavin adenine dinucleotide, and from 590 to 1332 for binding molybdoptern (Mo-Co) (5). The missense mutation G172R is not in the predicted functional domain, but A932T and N1109T are in the domain for binding molybdoptern. A932T and N1109T are not in the domain for binding flavin adenine dinucleotide, which is thought to play a major role in the conversion of XDH to XO and which increases ROS production in some pathological conditions, including hypertension and atherosclerosis (5) . However, it is important to note a recent report that XOR has both inorganic nitrate reductase and nitrite reductase activity at its Mo-Co site (42, 43) . This implies that an amino acid mutation at the Mo-Co site may influence nitric oxide production and modulate ROS production. Those four hypertensive patients with A932T and N1109T in the homozygous form all had high blood pressure, N1109T showed significant associations with hypertension and blood pressure, and the Mo-Co-binding site is the most conserved region of XDH among human, rat, and mouse (44) . This strongly indicates that the mutations A932T and N1109T may be functional risk factors for hypertension. Further in vivo and in vitro studies are needed to clarify this point.
Both 69901A>C and 66292C>G SNPs are in intron regions, while 47686C>T is a synonymous variation and, as such, is probably not functional. These SNPs are considered preferable as genetic markers. Human XDH is located on chromosome 2 at p23.1. Recently, Angius et al. reported strong evidence that a 0.54-cM region of chromosome 2 (2p 26.5-27.1) harbors a locus-affecting risk of hypertension in an isolated Sardinian population (45) . In addition, a number of regions of chromosome 2 (57-59, 86, 103, and 96-115 cM) have been found likely to harbor blood-pressure-modifying loci (45) (46) (47) (48) . More importantly, our group recently reported some hypertension-susceptibility genes at 2p24-p25 and a positive relationship between hypertension and SNPs of the Na + /Ca 2+ exchanger 1 gene, which is located at 2p22-p23, in a general Japanese population (49, 50) . Expanded genotyping and a detailed cross-study of candidate genes are necessary.
In summary, in human XDH, we found three SNPs, 47686C>T, 67873A>C, and 69901A>C, that are significantly associated with hypertension. Another SNP, 66292C>G, was significantly associated with CKD, and 69901A>C also showed a positive relation to carotid atherosclerosis in hypertensive patients. These SNPs may be independent risk factors for hypertension or CKD and carotid atherosclerosis in hypertensive patients. There was a limitation in this study owing to its cross-sectional design. Prospective studies investigating the relationships between these SNPs and the development of hypertension, CKD, and atherosclerosis over a long term are necessary. These gene polymorphisms in XDH may be useful for predicting and preventing hypertension and its complications in future individualized treatment.
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